Chester County News and Community Website
BERWYN, PA — Virpax Pharmaceuticals, Inc. (NASDAQ: VRPX) recently announced its financial results for the three months ended June 30, 2023, and other recent developments.
Virpax Pharmaceuticals Reports 2023 Second Quarter Results, Recent Developments Read More BERWYN, PA — Virpax® Pharmaceuticals, Inc. (NASDAQ: VRPX) announced that it recently filed a new provisional patent application with the United States Patent and Trademark Office (‘USPTO’) entitled “NSAID Formulation …
Virpax Pharmaceuticals Files Provisional Patent Application for NSAID Formulation and Method Read More BERWYN, PA — Virpax® Pharmaceuticals, Inc. (NASDAQ: VRPX) announced that it recently filed a new provisional patent application with the United States Patent and Trademark Office (‘USPTO’) entitled “Intranasal Delivery” related …
Virpax Pharmaceuticals Files Provisional Patent Application for Intranasal Delivery Read More BERWYN, PA — Virpax®Pharmaceuticals, Inc. (NASDAQ: VRPX) recently announced that it has entered into a cooperative research and development agreement (CRADA) with the National Institute of Neurological Disorders and Stroke …
Virpax Pharmaceuticals Enters into CRADA with the National Advisory Neurological Disorders and Stroke Council Read More BERWYN, PA — Virpax® Pharmaceuticals, Inc. (NASDAQ: VRPX) announced that Company CEO Anthony P. Mack has been invited to present at the Healthcare Virtual Conference Part II, presented by Maxim Group LLC …
Virpax Pharmaceuticals to Participate in the Healthcare Virtual Conference Read More BERWYN, PA — Virpax® Pharmaceuticals, Inc. (NASDAQ: VRPX) announced that it has engaged Dr. Pardeep Gupta, a leading expert in liposomal drug delivery and nanotechnology, to support the development of Probudur, Virpax’s …
Virpax Pharmaceuticals Enlists Leading Expert for Development of Pain Management Injectable Read More BERWYN, PA — Virpax® Pharmaceuticals, Inc. (NASDAQ: VRPX) announced recent progress made in its Envelta development program. Envelta is the Company’s non-opioid pain product candidate for acute and chronic pain that …
Virpax Reports on Progress of Envelta Read More BERWYN, PA — Virpax® Pharmaceuticals, Inc. (NASDAQ: VRPX) announced that the Company recently appointed Barbara A. Ruskin, Ph.D, J.D. to its Board of Directors, increasing the size of the Board to …
Virpax Pharmaceuticals Announces Appointment of Barbara A. Ruskin, Ph.D, J.D. to the Board of Directors Read More BERWYN, PA — Virpax Pharmaceuticals, Inc. (NASDAQ: VRPX) recently announced its financial results for the twelve months that ended December 31, 2022, and other recent developments.
Virpax Pharmaceuticals Reports 2022 Year-End Results Read More BERWYN, PA — Virpax® Pharmaceuticals, Inc. (NASDAQ: VRPX) announced that the Company has recently completed FDA-required preclinical toxicology studies for its licensed Molecular Envelope Technology (MET). MET enhances the delivery of …
Virpax Announces Positive Preclinical Toxicology Results in Support of Molecular Envelope Technology Read More